Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

HLS Therapeutics to Become Distributor of the Saladax MyCare(TM) Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents
- CNW Group - Mon Jun 1, 5:30AM CDT
CNW Group - CMTX
Mon Jun 1, 5:30AM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces that it has become the exclusive Canadian distributor for the MyCareTM Insite point-of-care device and its related line of diagnostic tests from Saladax Biomedical, Inc. ("Saladax") of Bethlehem, Pennsylvania.
HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa� (Icosapent Ethyl) against COVID-19
- CNW Group - Thu May 21, 3:07PM CDT
CNW Group - CMTX
Thu May 21, 3:07PM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in collaboration with Amarin Corporation (NASDAQ:AMRN) it is supporting a trial to investigate the effects of Vascepa® (icosapent ethyl, or "IPE") on inflammatory biomarkers in individuals with COVID-19. The trial sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, is being led by Dr. Subodh Verma MD, PhD, FRCSC, FAHA, a cardiac surgeon?scientist at St Michael's Hospital in Toronto, Professor at the University of Toronto and Canada Research Chair in Cardiovascular Surgery, and Dr. Deepak L. Bhatt MD MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and Professor, Harvard Medical School.
HLS Therapeutics Announces Q1 2020 Financial Results
- CNW Group - Thu May 7, 5:30AM CDT
CNW Group - CMTX
Thu May 7, 5:30AM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces its financial results for the three-month period ended March 31, 2020 ("Q1 2020"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
HLS Therapeutics to Host Q1 2020 Financial Results Conference Call
- CNW Group - Thu Apr 30, 5:30AM CDT
CNW Group - CMTX
Thu Apr 30, 5:30AM CDT
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, May 7, 2020. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Financial Officer. To participate on the call, please enter a dial-in number below and then enter the Conference ID when prompted.
HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)
- CNW Group - Tue Jan 28, 5:30AM CST
CNW Group - CMTX
Tue Jan 28, 5:30AM CST
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, is pleased to update investors that Vascepa(®) (icosapent ethyl, or "IPE") will become available to Canadians on or about February 18, 2020. At launch, Vascepa will be supported by the Company's national Cardiovascular salesforce, initially sized at 22 representatives, in addition to eight other field-based roles.
HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada
- CNW Group - Thu Jan 23, 5:30AM CST
CNW Group - CMTX
Thu Jan 23, 5:30AM CST
If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia
IIROC Trade Resumption - HLS
- PR Newswire - Tue Jan 7, 6:51AM CST
PR Newswire - PRNW
Tue Jan 7, 6:51AM CST
TORONTO , Jan. 7, 2020 /CNW/ - Trading resumes in:
HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events
- CNW Group - Tue Dec 31, 12:00PM CST
CNW Group - CMTX
Tue Dec 31, 12:00PM CST
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, is pleased to announce that Health Canada has approved the use of Vascepa® (icosapent ethyl) to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor. HLS in-licensed the exclusive rights to Vascepa for the Canadian market from Amarin Corporation (NASDAQ:AMRN) in 2017.
IIROC Trading Halt - HLS
- PR Newswire - Tue Dec 31, 11:07AM CST
PR Newswire - PRNW
Tue Dec 31, 11:07AM CST
TORONTO , Dec. 31, 2019 /CNW/ - The following issues have been halted by IIROC:
HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa
- CNW Group - Fri Nov 15, 5:30AM CST
CNW Group - CMTX
Fri Nov 15, 5:30AM CST
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that the Endocrinologic and Metabolic Drugs Advisory Committee ("EMDAC") of the U.S. Food and Drug Administration ("FDA") yesterday voted unanimously (16-0) that Amarin Corporation plc (NASDAQ: AMRN) provided sufficient evidence of efficacy and safety to support the approval of Vascepa(®) (icosapent ethyl) capsules for an indication and label expansion to reduce the risk of cardiovascular events in high risk patients based on results from the landmark REDUCE-ITTM cardiovascular outcomes trial.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies